Contineum Therapeutics (CTNM)

Executive Summary

Contineum Therapeutics (NASDAQ: CTNM) is a clinical-stage biopharmaceutical company developing oral small molecule therapies for neuroscience, inflammation, and immunology. Its lead asset, PIPE-307, a selective M1 receptor antagonist, recently completed a Phase 2 trial in relapsing-remitting multiple sclerosis (RRMS) with top-line data expected to be disclosed. The company is also advancing PIPE-791, an LPA1 receptor antagonist, which is being investigated in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF) that is currently recruiting patients. Additionally, PIPE-791 showed potential in chronic pain indications in early studies. With a focused pipeline and recent completion of key trials, Contineum is positioned to announce pivotal data in the near term, which could drive significant value.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 PIPE-307 RRMS top-line data release70% success
• H2 2026Phase 2 PIPE-791 IPF interim data60% success
• TBDPotential partnership for PIPE-307 in depression50% success